Patient Access Insights

Cross Border Healthcare – Challenges & Opportunities for Rare Disease Patients

In this webinar, we were delighted to be joined by a panel of experts who discussed the challenges facing patients with rare diseases and considering solutions.
Request this webinar

Cross Border Healthcare – Challenges & Opportunities for Rare Disease Patients

Request this webinar

Originally Broadcast: Tuesday 9th March 2021 13.30 - 14.30 GMT

Duration: 90 minutes. Available to watch on demand

Learning objectives:

  •  Understand the opportunities and challenges of cross border healthcare

  •  Learn about the perspective and experiences of companies, payers & the European Commission

  •  Understand the legal background to obtain reimbursement for a treatment in other EU countries

  •  What is the right point in time to get in contact and whom to approach?

  •  To what extent are national HTAs / submissions needed?

  •  Have there been experiences with orphan drugs and cell and gene therapies?

  •  Understand potential pathways in the EU 4 countries and in the UK

  •  What are the timelines and procedures needed under the S2 (social security) pathway?

Who would benefit from registering to attend this webinar:

This webinar should be attended by those interested in cell and gene therapies and orphan medicines and how they can remove obstacles to patient access. This is aimed at BioPharma and MedTech companies as well as patient organisations and patient groups.

The job functions that will benefit most include:

• Heads of Market Access

• Managing Directors

• Country Managers

• Chief Executives

• Health Economists

• Medical Directors

• Commercial Directors

• Policy Officers/Executives

• Marketing Directors

• Policy Advisors


Martin Dorazil, Deputy Head of Unit DG SANTE, European Commission

Simone Boselli, Director of Public Affairs, EURORDIS

Michela Gabaldo, Head Alliance Management & Regulatory Affairs, Fondazione Telethon

Diane Kleinermans, President of the Commission of Drugs Reimbursement, INAMI-RIZIV

Thomas Bols, Head of Government Affairs and Public Policy, EMEA & APAC, PTC Therapeutics, Inc

Dr Alex Natz, EUCOPE

Alexander Natz is the Secretary General of the European Confederation of Pharmaceutical Entrepreneurs ( in Brussels and works as a lawyer in the healthcare boutique law firm NOVACOS in Düsseldorf ( He advises innovative pharmaceutical and biotech companies, including start-ups, in regulatory and pricing & reimbursement matters from the EU law and German law perspective.

From 2008 to 2013, he was Head of the Brussels Office of Bundesverband der Pharmazeutischen Industrie eV (BPI). Before, he has been a lawyer at Sträter Law Firm in Germany with a special focus on managed entry agreements and licensing of pharmaceuticals. Dr. Natz has also worked in the field of competition law with the European Commission and in the pharmaceutical industry.

Christian Hill, CEO MAP BioPharma

Christian is a seasoned Market Access professional with over 20 years of experience in the International Biotech and Pharmaceutical industry. He has been involved in over 50 HTAs across Europe and has built up a strong network of key influencers including EU and national agencies. Prior to co-founding MAP in 2012, he led market access teams and submissions at InterMune, Gilead, Pfizer and Genzyme on a very broad range of products and disease areas from chronic disease to ultra-orphan indications.

Christian is a member of the Board of EUCOPE (European Confederation of Pharmaceutical Entrepreneurs); he is also a member of the Steering Group of EMIG (Ethical Medicines Industry Group) in the UK and Ireland.

CareersTerms and ConditionsComplaints ProcedurePrivacy PolicyCookie Policy

Copyright © 2021.
MAP BioPharma Limited.
All rights reserved.

MAP BioPharma Limited
Upper Pendrill Court, Ermine Street North
Papworth Everard, Cambridge
Cambridgeshire, CB23 3UY
United Kingdom

 +44 (0) 1480 832360

MAP BioPharma Limited is a registered company in England and Wales.
Company Registration Number 08209281

VAT Group Registration Number:
GB 292 8576 52